Robert J. Glynn

Robert J. Glynn

Auto-generated profile, based on publicly available information

Robert J. Glynn

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JGJoshua J. Gagne
Joshua J. Gagne
RGRobert J. Glynn
Robert J. Glynn
JAJerry Avorn
Jerry Avorn
RLRaisa Levin
Raisa Levin
SSSebastian Schneeweiss
Sebastian Schneeweiss

30 April 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RGRobert J. Glynn
Robert J. Glynn
EDEleanor Danielson
Eleanor Danielson
FFFrancisco A.H. Fonseca
Francisco A.H. Fonseca
JGJacques Genest
Jacques Genest
AGAntonio M. Jr. Gotto
Antonio M. Jr. Gotto
PRPaul M Ridker
Paul M Ridker
Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis and whether treatments of known efficacy for one disease process have consistent benefits for the other. Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking. We randomly assigned 17,802 apparently healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg per day, or placebo. We followed participants for the first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an intention-to-treat basis. During a median follow-up period of 1.9 years (maximum, 5.0), symptomatic venous thromboembolism occurred in 94 participants: 34 in the rosuvastatin group and 60 in the placebo group. The rates of venous thromboembolism were 0.18 and 0.32 event per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio with rosuvastatin, 0.57; 95% confidence interval [CI], 0.37 to 0.86; P=0.007); the corresponding rates for unprovoked venous thromboembolism (i.e., occurring in the absence of a known malignant condition, trauma, hospitalization, or surgery) were 0.10 and 0.17 (hazard ratio, 0.61; 95% CI, 0.35 to 1.09; P=0.09) and for provoked venous thromboembolism (i.e., occurring in patients with cancer or during or shortly after trauma, hospitalization, or surgery), 0.08 and 0.16 (hazard ratio, 0.52; 95% CI, 0.28 to 0.96; P=0.03). The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; P=0.004). Consistent effects were observed in all the subgroups examined. No significant differences were seen between treatment groups in the rates of bleeding episodes. In this trial of apparently healthy persons, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism. (ClinicalTrials.gov number, NCT00239681.)

5 October 2005 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
RGRobert J. Glynn
Robert J. Glynn
BRBernard Rosner
Bernard Rosner
Methods for formal comparison of competing risks may clarify uncertainties about the associations of atherosclerotic risk factors with the development of venous thromboembolism (VTE). For a median of 20.1 years, the Physicians' Health Study (1982–2003) followed 18,662 US male physicians with no prior myocardial infarction, stroke, VTE, or cancer and for whom reported risk factor information was available at baseline. The authors used methods of competing risk survival analysis to compare relative hazard rates associated with age, hypertension, elevated cholesterol, diabetes, cigarette smoking, alcohol consumption, exercise frequency, body mass index, and height. During follow-up, coronary heart disease (CHD) occurred first in 1,348 men, stroke in 902 men, and VTE in 358 men. Incidence of all three outcomes increased with age, but the rate of increase was strongest for stroke. Hypertension, elevated cholesterol, diabetes, and smoking were associated with increased rates of CHD and stroke, with comparable magnitudes, but had no association with VTE. Conversely, higher body mass index was more strongly associated with risk of VTE than of either CHD or stroke, and taller men had a significantly increased risk of VTE but a lower risk of CHD. CHD and stroke have broadly comparable risk factor profiles that differ widely from the profile for VTE.

3 February 1999 in JAMA
Verified
Journal Article
Open access
PDF file
RGRobert J. Glynn
Robert J. Glynn
LBLaurel A. Beckett
Laurel A. Beckett
LHLiesi E. Hebert
Liesi E. Hebert
MMMartha Clare Morris
Martha Clare Morris
PSPaul A. Scherr
Paul A. Scherr
DEDenis A. Evans
Denis A. Evans
High blood pressure (BP) is an important risk factor for vascular disease, including stroke, in the elderly.1,2 Because vascular disease can lead to dementia,3,4 this suggests a possible association between elevated BP and increased risk of dementia. However, the findings of cross-sectional, population-based studies of BP and cognitive function in the elderly have varied greatly. Some studies found higher rates of cognitive impairment associated with elevated BP,5 others with low BP,6 and other studies found little or no association.7 These results mirror the conflicting associations between BP and cardiovascular disease mortality found in observational studies of the elderly.8

21 April 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
CDColin R. Dormuth
Colin R. Dormuth
APAmanda R. Patrick
Amanda R. Patrick
WSWilliam H. Shrank
William H. Shrank
JWJames M. Wright
James M. Wright
RGRobert J. Glynn
Robert J. Glynn
MBM. Alan Brookhart
M. Alan Brookhart
Background— Bias in studies of preventive medications can occur when healthier patients are more likely to initiate and adhere to therapy than less healthy patients. We sought evidence of this bias by examining associations between statin exposure and various outcomes that should not be causally affected by statin exposure, such as workplace and motor vehicle accidents. Methods and Results— We conducted a prospective cohort study of statin patients using data from British Columbia, Canada, a multiethnic society with a population of 4.3 million people. Study subjects were 141 086 patients who initiated statins for primary prevention. We examined the association between adherence and multiple outcomes such as accidents and screening procedures using multivariable-adjusted Cox proportional hazards models. The study population was 49% female and had an average age of 61 years. The results from our multivariable-adjusted models showed that more adherent patients were less likely to have accidents than less adherent patients. This effect was greatest for motor vehicle accidents (hazard ratio, 0.75; 95% confidence interval, 0.72 to 0.79) and workplace accidents (hazard ratio, 0.77; 95% confidence interval, 0.74 to 0.81). More adherent patients had a greater likelihood of using screening services (hazard ratio, 1.17; 95% confidence interval, 1.15 to 1.20) and a lower likelihood of developing other diseases likely to be unrelated to a biological affect of a statin (hazard ratio, 0.87; 95% confidence interval, 0.86 to 0.89). Conclusions— Our study contributes compelling evidence that patients who adhere to statins are systematically more health seeking than comparable patients who do not remain adherent. Caution is warranted when interpreting analyses that attribute surprising protective effects to preventive medications.

9 October 2000 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
RGRobert J. Glynn
Robert J. Glynn
CCClaudia U. Chae
Claudia U. Chae
JGJack M. Guralnik
Jack M. Guralnik
JTJames O. Taylor
James O. Taylor
CHCharles H. Hennekens
Charles H. Hennekens
IN MIDDLE-AGED populations, both systolic and diastolic blood pressure have strong, linear relationships with cardiovascular and total mortality.1-5 Because of the high correlation between systolic and diastolic pressure, studies examining cardiovascular risk in this age group commonly find that diastolic pressure provides little additional prognostic information after consideration of systolic pressure.1-4 In older people, however, observational studies have been less consistent6-13 and have commonly found U- or J-shaped relationships of blood pressure with mortality, especially for diastolic pressure. In some studies, individuals with the lowest blood pressure had the highest mortality.14,15 Treatment implications of these relationships remain controversial.16-20 With the loss of aortic compliance, systolic pressure rises with age in industrialized countries, while diastolic pressure declines after about age 60 years, leading to increased pulse pressure and a diminished association between systolic and diastolic pressure.21 This may lead to differing relationships of systolic and diastolic pressure with mortality in older people.